Viral Inactivation
Viral Inactivation - Related Videos
03:41
Assessing the Effectiveness of an Antiviral Test Compound through a Viral Inactivation Assay
0 Views •
2025
This video demonstrates the viral inactivation assay, showcasing the evaluation of the impact of antiviral agents on viral particles.
01:58
X-Inactivation
0 Views •
2019
The human X chromosome contains over ten times the number of genes as in the Y chromosome. Since males have only one X chromosome, and females have two, one might expect females to produce twice as many of the proteins, with undesirable results. Instead, in order to avoid this potential issue, female mammalian cells inactivate nearly all the genes in one of their X chromosomes during early embryonic development. In the nuclear envelope surrounding the cell nucleus, the inactivated X chromosome...
01:58
X-inactivation
0 Views •
2021
The human X chromosome contains over ten times the number of genes as in the Y chromosome. Since males have only one X chromosome, and females have two, one might expect females to produce twice as many of the proteins, with undesirable results. Instead, in order to avoid this potential issue, female mammalian cells inactivate nearly all the genes in one of their X chromosomes during early embryonic development. In the nuclear envelope surrounding the cell nucleus, the inactivated X chromosome...
01:22
Activation and Inactivation of G Proteins
0 Views •
2023
Heterotrimeric G proteins are guanine nucleotide-binding proteins. As the name suggests, heterotrimeric G proteins are composed of three subunits: alpha, beta, and gamma. They remain GDP-bound or GTP-bound inside the cells and switch between inactive/active states. The Gα subunit possesses the nucleotide-binding pocket that binds guanine nucleotides and switches between GDP or GTP-bound states. In contrast, the Gꞵ and Gγ subunits are always bound together with high affinity and are together...
03:19
Inactivation of Bacteria Using Light-Activated Flavin Mononucleotide
0 Views •
2025
Source: Cheng, C., et al. Inactivation of Pathogens via Visible-Light Photolysis of Riboflavin-5′-Phosphate. J. Vis. Exp. (2022)This video demonstrates a method for evaluating the phototoxic effects of flavin mononucleotide (FMN) on pathogenic bacteria. Bacterial cultures are exposed to increasing concentrations of FMN and illuminated with visible light to generate reactive oxygen species (ROS) that damage cellular components. The surviving bacteria are then quantified to assess the...
FAQs
The virus’s physical structures determine which targets a treatment can damage. Envelopes and capsid proteins can be affected differently from nucleic acids, and the resulting loss of infectivity depends on the virus’s structure. Recognizing these targets helps researchers choose conditions that are effective against the virus while supporting the intended use of the treated material.
Heat, pH changes, ultraviolet radiation, and chemical agents do not provide interchangeable effects. Each treatment applies a different controlled condition, while effectiveness also depends on the virus being treated. Consequently, an approach that works for one virus may not produce the same outcome for another, making treatment conditions a central part of experimental design.
Successful treatment requires balancing two goals: eliminating infectivity and retaining relevant properties of the surrounding material when possible. More intensive conditions may improve viral damage but can also alter the material being preserved. Researchers therefore consider both the virus structure and the desired properties of the sample when selecting an inactivation approach.
Selection begins with the sample’s intended use, the virus structure, and the available treatment condition. Researchers then apply controlled heat, pH, ultraviolet, or chemical conditions and validate that the process removes the virus’s ability to infect cells. Validation is essential because treatment exposure alone does not establish successful inactivation.
In immunology and infection research, validated inactivation supports safer handling of infectious samples and can contribute to preparing some vaccines and biologic products. It is especially relevant when the surrounding material must remain useful after treatment. The validation step connects a safety objective with evidence that infectivity has been eliminated under the selected conditions.
Researchers can use validated inactivation when examining whether antibodies or other interventions reduce infectivity. The key outcome is not simply that a treatment was applied, but whether the virus can still infect cells after the relevant experimental conditions. This makes inactivation and infectivity assessment important components of studies of immune or therapeutic effects.